Exclusion criteria included a height that was less than 2 SD below the mean or greater than 2 SD above the mean on achondroplasia growth charts ... 11.5), and 58% were female.

A promising daily tablet is effective at increasing height and improving proportional limb growth in children with ...

New drug shown to improve bone growth in children with achondroplasia Date: September 8, 2020 Source: Murdoch Childrens Research Institute Summary: A phase three global clinical trial has shown ...

30 Once-daily subcutaneous administration of vosoritide promotes long-bone growth in juvenile, skeletally normal mice and monkeys and corrects the dwarfism phenotype in mice with achondroplasia.

Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling ...

Additionally, improvements were noted in lower limb alignment, proportional growth, and spinal canal dimensions. Achondroplasia is caused by a variant in the FGFR3 gene and affects over 250,000 ...

William Blair notes that the efficacy of TransCon CNP is comparable to BioMarin’s Voxzogo (vosoritide), which is approved for promoting linear growth in children with achondroplasia and open ...